About this episode
Dillan DiNardo, Co-Founder and CEO of Mindstate Design Labs, returns to the Mycopreneur Podcast to share updates on the companies progress as a clinical-stage AI neuroengineering platform and drug development outfit. We explore how Mindstate Design is leveraging artificial intelligence in their drug development process, discuss the origins of the company and it's connection to legendary drug chemist Alexander "Sasha" Shulgin, and cover the evolving landscape of psychedelic drug research and where it could all go from here.
Please rate and review wherever you're listening ( :
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Mycopreneur publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Mycopreneur
Lee Carroll: Ergothioneine in Support of Psychedelic Therapy
Mycopreneur
Adam Miezio: Psychedelics in the Epstein Files
Mycopreneur
Robert Gallery: Ibogaine For Athletes with Traumatic Brain Injuries
Mycopreneur
Melanie Tremblay: The Hidden Dangers of AI-Generated Mushroom Claims
Mycopreneur